New Obesity Drug Poised To Upend Weight Loss Care

(AP) – A diabetes drug being tested for weight loss is poised to further upend obesity care. Drug-maker Eli Lilly reported Thursday that Tirzepatide helped people with diabetes who were overweight or had obesity lose up to 16% of their body weight over 17 months in a late-stage trial. For those without the disease, the drug has prompted losses of more than 20% of body weight. Known as Mounjaro for diabetes use, the drug has been used “off label” for weight loss since last year. Lilly is applying for fast-track approval from U.S. regulators. Analysts have predicted tirzepatide could become one of the top-selling drugs ever, with annual sales topping $50 billion.